FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Ipsen NDA Resubmission for Palovarotene

[ Price : $8.95]

FDA accepts for review an Ipsen resubmitted NDA for palovarotene as a potential treatment for fibrodysplasia ossificans progressiv...

Sarepta BLA Needs Panel Review: FDA

[ Price : $8.95]

FDA tells Sarepta Therapeutics that it has decided to hold an advisory committee meeting to review its gene therapy BLA for SRP-90...

Guide on Pharmacogenomic Data Submissions

[ Price : $8.95]

FDA posts a draft guidance entitled Pharmacogenomic Data Submissions that discusses the use of such data in drug development.

CDER Regulatory Site Tours Continue

[ Price : $8.95]

Federal Register notice: CDER announces the continuation of its Regulatory Project Management Site Tours and Regulatory Interactio...

FDA Hits Olympus with Warning Letter

[ Price : $8.95]

FDA issues Olympus Medical Systems a Warning Letter after inspecting the firms Tokyo facility and documenting GMP deficiencies.

Court OKs $25 Million Remicade Settlement

[ Price : $8.95]

A federal judge approves a $25 million class action settlement involving Johnson & Johnsons Remicade (infliximab).

CDER Posts Annual Office of Compliance Report

[ Price : $8.95]

CDER posts its Office of Compliance Annual Report for fiscal year 2022.

Datascopes Cardiosave Heart Pumps Recalled

[ Price : $8.95]

Datascope/Getinge recalls Cardiosave Hybrid IABPs and Rescue IABPs because the coiled cable connecting the display and base on som...

Medical Foods Q&A Guidance

[ Price : $8.95]

FDA publishes an updated question-and-answer guidance on the definition and regulation of medical foods.

Drug Supply Guide on Illegitimate/Suspect Products

[ Price : $8.95]

Federal Register notice: FDA posts a final guidance entitled Definitions of Suspect Product and Illegitimate Product for Verificat...